NI-62 * DCE-MRI DISCRIMINATES BETWEEN RESPONDER AND NON-RESPONDER IN PROGRESSIVE HIGH GRADE GLIOMA PATIENTS UNDERGOING ANTI-ANGIOGENIC TREATMENT
نویسندگان
چکیده
منابع مشابه
Treatment Modalities in Poor Responder Patients Undergoing Assisted Reproductive Techniques
Successful IVF/ICSI treatment depends on obtaining a sufficient oocyte sample and selecting patients carefully. COH (Controlled Overian Hyperstimulation) treatment in patients with poor ovarian response is one of the most important issues in IVF programmes. The ovarian response that follows ovarian stimulation is the most important determiner in ART treatment. Although many other stimulation pr...
متن کاملInvestigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran
Background Methadone therapy is a major protocol in opioid addiction cases in many health care systems. Population-based studies have shown that in addicted people, the genetic profile affects their response to methadone therapy. Therefore, this study designed to examine the frequency of two SNPs of the CYP2B6 gene (rs3745274 and rs3211371) in addicted cases in two methadone-responders and meth...
متن کاملRituximab for Treatment of Hemophilia A with High-Responder Inhibitors
Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...
متن کاملDistribution of Circulating Immune Cells in Responder and Non-Responder Individuals to Hepatitis B Vaccine
Unresponsiveness to hepatitis B surface antigen (HBsAg) has been shown to be associated with dysfunction of the presenting cells (APC) and defect in the specific B-lymphocyte and/or T-lymphocyte repertoires. Direct determination of the frequency of specific T-lymphocytes together with complementary analysis of the naive circulating immune cells could provide valuable information about the cel...
متن کاملOmalizumab: when the non-responder is a late-responder.
UNLABELLED Omalizumab is an anti-IgE monoclonal antibody available since 2006 for the treatment of GINA step 4 asthma. We studied a 41-year old male who has been suffering from severe steroid-resistant asthma with severe co-morbidity and treated with Omalizumab. He was found to be non-responder to the treatment until the 48th week, starting from which we began to see a distinct improvement in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2014
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/nou264.60